Sign in
Active, not recruitingPhase 1

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Key facts

Who runs it
GC Biopharma Corp
Where
Minneapolis and Oakland, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
9 people, planned
Started
21 Nov 2024
Expected to end
Jun 2027
Type of study
Interventional, 3 groups
Treatments tested
  • GC1130A
Record updated
8 September 2026

Who can take part

Age
12 months to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants with documented MPS IIIA diagnosis
  • Participants aged ≥ 12 months and ≤ 18 years

Who cannot take part

  • Participants with previous complication from intraventricular drug administration
  • Participants that received treatment with any investigational drug or a device intended as a treatment for MPS IIIA within 30 days or 5 half-lives prior to the study
  • Participants that received a hematopoietic stem cell or bone marrow transplant or received gene therapy
  • Participants with significant non-MPS IIIA related central nervous system impairment
  • Participants with contraindications for MRI scans and for neurosurgery

Where in United States

Also in 1 other country, 2 sites

  • University of MinnesotaMinneapolis, United States
  • UCSF Benioff Children s HospitalOakland, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

The 3 groups in the trial

  • Cohort 1Treatment being tested

    Treatment: GC1130A

  • Cohort 2Treatment being tested

    Treatment: GC1130A

  • Cohort 3Treatment being tested

    Treatment: GC1130A

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Open-label, Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A) Via Intracerebroventricular Access Device in Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Record updated
8 September 2026